BACKGROUND: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). METHODS: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. RESULTS: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD. CONCLUSIONS: The CGMS demonstrated the benefits of ITx in T1DM, with improvements in glycemic control apparent up to 18 months after transplant. CGMS measures were found to be indicators of GD.
BACKGROUND: This study evaluated the effects of islet allotransplantation (ITx) on metabolic control utilizing a continuous glucose monitoring system (CGMS) and assessed its effectiveness as an indicator and predictor of graft dysfunction (GD). METHODS: Glycemic control was assessed in 25 patients with type 1 diabetes mellitus (T1DM); 12 ITx recipients and 13 controls. Mean interstitial glucose, standard deviation (SD), glucose variability, and percentage of time in hyperglycemia (%GT >140 mg/dl), hypoglycemia (%GT <54 mg/dl), and normoglycemia (%GT 54-140 mg/dl) were measured in 72-hour time periods from CGMS recordings in the control group at baseline and in the ITx group at 3, 6, 9, 12, 15, and 18 months after ITx completion and were analyzed as predictors and indicators of GD. Hemoglobin A1c (HbA1c), 90-minute glucose after a mixed meal tolerance test, fasting C-peptide/glucose ratio, and insulin requirements were followed. RESULTS: Compared to the control group, the percentage of time in hypoglycemia was significantly lower in the ITx group at all time points; time in normoglycemia was increased at all times except at 15 months; and time in hyperglycemia was significantly lower at 6, 9, 12, and 18 months. Mean glucose and glucose variability were significantly lower in the ITx group at all times except at 3 and 15 months, whereas HbA1c and 90-minute glucose were significantly lower in the ITx group at all time points. Mean glucose, SD, glucose variability, and %GT >140 mg/dl were significant as indicators but not as predictors of GD. CONCLUSIONS: The CGMS demonstrated the benefits of ITx in T1DM, with improvements in glycemic control apparent up to 18 months after transplant. CGMS measures were found to be indicators of GD.
Authors: R Poggioli; R N Faradji; G Ponte; A Betancourt; S Messinger; D A Baidal; T Froud; C Ricordi; R Alejandro Journal: Am J Transplant Date: 2006-02 Impact factor: 8.086
Authors: Breay W Paty; Peter A Senior; Jonathan R T Lakey; A M James Shapiro; Edmond A Ryan Journal: Diabetes Technol Ther Date: 2006-04 Impact factor: 6.118
Authors: R N Faradji; K Monroy; A Riefkohl; L Lozano; L Gorn; T Froud; P Cure; D Baidal; G Ponte; S Messinger; J Mastrototaro; C Ricordi; R Alejandro Journal: Transplant Proc Date: 2006-12 Impact factor: 1.066
Authors: Milene C Geiger; Jacqueline V Ferreira; Muhammad M Hafiz; Tatiana Froud; David A Baidal; Luigi F Meneghini; Camillo Ricordi; Rodolfo Alejandro Journal: Cell Transplant Date: 2005 Impact factor: 4.064
Authors: Michael R Rickels; Mark H Schutta; Rebecca Mueller; James F Markmann; Clyde F Barker; Ali Naji; Karen L Teff Journal: Diabetes Date: 2005-11 Impact factor: 9.461
Authors: A M James Shapiro; Camillo Ricordi; Bernhard J Hering; Hugh Auchincloss; Robert Lindblad; R Paul Robertson; Antonio Secchi; Mathias D Brendel; Thierry Berney; Daniel C Brennan; Enrico Cagliero; Rodolfo Alejandro; Edmond A Ryan; Barbara DiMercurio; Philippe Morel; Kenneth S Polonsky; Jo-Anna Reems; Reinhard G Bretzel; Federico Bertuzzi; Tatiana Froud; Raja Kandaswamy; David E R Sutherland; George Eisenbarth; Miriam Segal; Jutta Preiksaitis; Gregory S Korbutt; Franca B Barton; Lisa Viviano; Vicki Seyfert-Margolis; Jeffrey Bluestone; Jonathan R T Lakey Journal: N Engl J Med Date: 2006-09-28 Impact factor: 91.245
Authors: Ulrik Pedersen-Bjergaard; Stig Pramming; Simon R Heller; Tara M Wallace; Ase K Rasmussen; Hanne V Jørgensen; David R Matthews; Philip Hougaard; Birger Thorsteinsson Journal: Diabetes Metab Res Rev Date: 2004 Nov-Dec Impact factor: 4.876
Authors: Edmond A Ryan; Tami Shandro; Kristy Green; Breay W Paty; Peter A Senior; David Bigam; A M James Shapiro; Marie-Christine Vantyghem Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Pratik Choudhary; Michael R Rickels; Peter A Senior; Marie-Christine Vantyghem; Paola Maffi; Thomas W Kay; Bart Keymeulen; Nobuya Inagaki; Frantisek Saudek; Roger Lehmann; Bernhard J Hering Journal: Diabetes Care Date: 2015-06 Impact factor: 19.112
Authors: William T Cefalu; Dana K Andersen; Guillermo Arreaza-Rubín; Christopher L Pin; Sheryl Sato; C Bruce Verchere; Minna Woo; Norman D Rosenblum Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152
Authors: Federico Bertuzzi; Luciano De Carlis; Mario Marazzi; Antonio Gaetano Rampoldi; Matteo Bonomo; Barbara Antonioli; Marta Cecilia Tosca; Marta Galuzzi; Andrea Lauterio; Danila Fava; Patrizia Dorighet; Andrea De Gasperi; Giacomo Colussi Journal: Cell Transplant Date: 2018-06-05 Impact factor: 4.064